Published Online:22 Dec 2006https://doi.org/10.2217/14622416.8.1.29
Abstract
Introduction: The human multidrug resistance gene ATP-binding cassette B1 (ABCB1) codes for P-glycoprotein (P-gp), an important membrane-bound efflux transporter known to confer anticancer drug resistance as well as affect the pharmacokinetics of many drugs and xenobiotics. A number of single nucleotide polymorphisms (SNPs) have been identified throughout the ABCB1 gene that may have an effect on P-gp expression levels and function. Haplotype as well as genotype analysis of SNPs is becoming increasingly important in identifying genetic variants underlying susceptibility to human disease. Three SNPs, 1236C→T, 2677G→T and 3435C→T, have been repeatedly shown to predict changes in the function of P-gp. The frequencies with which these polymorphisms exist in a population have also been shown to be ethnically related. Methods: In this study, 95 individuals representative of the entire ethnic make-up of the USA were compared with 101 individuals from an Ashkenazi-Jewish population. These individuals were analyzed by genomic sequencing and polymerase chain reaction, using restriction fragment length polymorphisms, to calculate their genotype frequencies. Results: A total of 25 SNPs were located in the exons of the ABCB1 gene. All of the polymorphisms identified were in parts of the ABCB1 gene product predicted to be intracellular, and 16 appear to be novel as compared with those listed by the National Center for Biotechnological Information. Frequencies of the 1236C→T and 2677G→T/A/C SNPs were similar for the US and Ashkenazi populations (64.2 and 60.4%, respectively for 1236C→T [χ2: 0.30; p ≤ 1]; 55.8 and 64.4%, respectively for 2677G→T/A/C [χ2: 1.49; p ≤ 1]), but were different for 3435C→T (24.2% for the US population and 69.3% for the Ashkenazi population [χ2: 39.927; p ≤ 0.001]). The 1236T/ 2677T/3435T haplotype occurred in 23.6% (standard error: 0.013) of the Ashkenazi population. Conclusion: The SNP at location 3435C→T plays a significant role in the ABCB1 gene. The haplotype and genotype analysis from these data may be used as a basis for studies on the relationship between ABCB1 genotypes and drug efficacy, drug toxicity, disease susceptibility or other phenotypes.
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Bibliography
- 1 Borst P, Elferink RO: Mammalian ABC transporters in health and disease. Annu. Rev. Biochem.71,537–592 (2002).
- 2 Gottesman MM: Mechanisms of cancer drug resistance. Annu. Rev. Med.53,615–627 (2002).• Thorough review of the properties that lead to cancer drug resistance and the genes and drugs with clinical relevance to drug resistance.
- 3 Mayer U, Wagenaar E, Beijnen JH et al.: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol.119(5),1038–1044 (1996).
- 4 Lee CG, Gottesman MM, Cardarelli CO et al.: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry37(11),3594–3601 (1998).
- 5 Bogman K, Peyer AK, Torok M, Kusters E, and Drewe J: HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol.132(6),1183–1192 (2001).
- 6 Chiou WL, Chung SM, Wu TC, Ma C: A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther.39(3),93–101 (2001).
- 7 Venter JC, Adams MD, Myers EW et al.: The sequence of the human genome. Science291(5507),1304–1351 (2001).
- 8 Buckland PR: The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim. Biophys. Acta1762(1),17–28 (2006).
- 9 Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7),3473–3478 (2000).•• Showed a significant correlation between the polymorphism 3435C>T and MDR1 expression after digoxin administration.
- 10 Brinkmann U, Roots I, Eichelbaum M: Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today6(16),835–839 (2001).
- 11 Saito S, Iida A, Sekine A et al.: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet.47(1),38–50 (2002).
- 12 Evans WE, McLeod HL: Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med.348(6),538–549 (2003).
- 13 Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol.43,285–307 (2003).
- 14 Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther.70(2),189–199 (2001).• European–Americans and African–Americans have different frequencies ofMDR1 alleles in positions C1236T, C3435T, and G2677T. Showed that allelic variation in MDR1 commonly involves these three SNPs, which affect P-glycoprotein activity and function.
- 15 Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M: Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br. J. Clin. Pharmacol.59(3),365–370 (2005).
- 16 Behar DM, Hammer MF, Garrigan D et al.: MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population. Eur. J. Hum. Genet.12(5),355–364 (2004).
- 17 Behar DM, Metspalu E, Kivisild T et al.: The matrilineal ancestry of Ashkenazi Jewry: portrait of a recent founder event. Am. J. Hum. Genet.78(3),487–497 (2006).
- 18 Slatkin M: A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases. Am. J. Hum. Genet.75(2),282–293 (2004).
- 19 Gershoni-Baruch R, Shinawi M, Leah K, Badarnah K, Brik R: Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur. J. Hum. Genet.9(8),634–637 (2001).
- 20 King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302(5645),643–646 (2003).
- 21 Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med.351(19),1972–1977 (2004).
- 22 Tukel T, Shalata A, Present D et al.: Crohn disease: frequency and nature of CARD15 mutations in Ashkenazi and Sephardi/Oriental Jewish families. Am. J. Hum. Genet.74(4),623–636 (2004).
- 23 Ostrovsky O, Nagler A, Korostishevsky M, Gazit E, Galski H: Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel. Ther. Drug Monit.26(6),679–684 (2004).• Provided important data regarding the 3435C>T polymorphism frequencies in several Jewish populations in which Ashkenazi Jews showed the highest frequency of this SNP (0.65).
- 24 Kroetz DL, Pauli-Magnus C, Hodges LM et al.: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics13(8),481–494 (2003).•• Reported ABCB1 nucleotide and haplotype structure in several different populations, illustrating the importance of haplotype analysis and the functional consequences ofABCB1polymorphisms
- 25 Johne A, Kopke K, Gerloff T et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther.72(5),584–594 (2002).
- 26 Potocnik U, Ferkolj I, Glavac D, Dean M: Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun.5(7),530–539 (2004).
- 27 Zhao H, Pfeiffer R, Gail MH: Haplotype analysis in population genetics and association studies. Pharmacogenomics4(2),171–178 (2003).• Review on the importance of haplotype analysis in population genetics studies, discussing different methods of statistical analysis for population genetics.
- 28 Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet.68(4),978–989 (2001).
- 29 Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet.73(5),1162–1169 (2003).
- 30 Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene22(47),7468–7485 (2003).• In-depth review of P-glycoprotein, including biochemical data, mutation analysis within the TM domain and polymorphisms in the MDR1 gene that affect the pharmacokinetics of its substrates.
- 31 Asano T, Takahashi KA, Fujioka M et al.: ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics13(11),675–682 (2003).
- 32 Kurzawski M, Drozdzik M, Suchy J et al.: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur. J. Clin. Pharmacol.61(5–6),389–394 (2005).
- 33 Tan EK, Chan DK, Ng PW et al.: Effect of MDR1 haplotype on risk of Parkinson disease. Arch. Neurol.62(3),460–464 (2005).
- 34 Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP, Lyakhovich VV: Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull. Exp. Biol. Med.136(2),183–185 (2003).
- 35 Zhu D, Taguchi-Nakamura H, Goto M et al.: Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir. Ther.9(6),929–935 (2004).
- 36 Sills GJ, Mohanraj R, Butler E et al.: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia46(5),643–647 (2005).
- 37 Yamauchi A, Ieiri I, Kataoka Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation74(4),571–572 (2002).
- 38 van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ et al.: MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood97(11),3605–3611 (2001).
- 39 Meissner K, Jedlitschky G, Meyer zu Schwabedissen H et al.: Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics14(6),381–385 (2004).
- 40 Kurata Y, Ieiri I, Kimura M et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther.72(2),209–219 (2002).
- 41 Horinouchi M, Sakaeda T, Nakamura T et al.: Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm. Res.19(10),1581–1585 (2002).
- 42 Moriya Y, Nakamura T, Horinouchi M et al.: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull.25(10),1356–1359 (2002).
- 43 Tang K, Ngoi SM, Gwee PC et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics12(6),437–450 (2002).
- 44 Tanabe M, Ieiri I, Nagata N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther.297(3),1137–1143 (2001).
- 45 Furuno T, Landi MT, Ceroni M et al.: Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics12(7),529–534 (2002).
- 46 Markova S, Nakamura T, Sakaeda T et al.: Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation. Drug Metab. Pharmacokinet.21(3),194–200 (2006).
- 47 Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A silent polymorphism in the MDR1gene changes substrate specificity. Science (2007) (In press).•• Demonstrates that the silent polymorphism 3435C>T is responsible for a change in substrate binding in vitro, which results from conformation changes in the protein. Low codon usage of this SNP brings about this conformation change.
- 48 Sinues B, Fanlo A, Bernal ML et al.: MDR1 C3435T genetic polymorphism and tobacco-related lung cancer. Oncology64(2),183–185 (2003).
- 49 Siegsmund M, Brinkmann U, Schaffeler E et al.: Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol.13(7),1847–1854 (2002).
- 50 Jamroziak K, Mlynarski W, Balcerczak E et al.: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol.72(5),314–321 (2004).
- 51 Niell BL, Long JC, Rennert G, Gruber SB: Genetic anthropology of the colorectal cancer-susceptibility allele APC I1307K: evidence of genetic drift within the Ashkenazim. Am. J. Hum. Genet.73(6),1250–1260 (2003).
- 52 Kronn D, Jansen V, Ostrer H: Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, NY, USA. Arch. Intern. Med.158(7),777–781 (1998).
- 53 Pier GB, Grout M, Zaidi T et al.: Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature393(6680),79–82 (1998).
- 54 Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ: Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science266(5182),107–109 (1994).
- 55 Ameyaw MM, Regateiro F, Li T et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics11(3),217–221 (2001).
- 56 Li Y, Wang Y, Sun J, Li Y, Yang L: Distribution of the functional MDR1 C3435T polymorphism in the Han population of China. Swiss Med. Wkly136(23–24),377–382 (2006).
- 101 National Center for Biotechnological Information (NCBI) SNP database. www.ncbi.nlm.nih.gov/projects/SNP
- 102 Tel-Aviv University National Laboratory for the Genetics of Israeli Populations homepage. http://nlgip.tau.ac.il
- 103 New England Biolabs® Inc. NEBcutter V2.0 information page. http://tools.neb.com/NEBcutter2/index. php
- 104 University of California, Santa Cruz, Genome Bioinformatics homepage. http://genome.ucsc.edu
